Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)
AstraZeneca bets up to $1.8B on CinCor and its ex-Roche drug for hypertension
CinCor Pharma’s hypertension drug may have failed a Phase II study, but that doesn’t scare AstraZeneca.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
